InventisBio’s psoriasis drug meets phase 3 endpoints, with over 70% of patients achieving a 90% improvement in skin lesion scores
Oral TYK2 inhibitor nomelcitinib showed an efficacy signal in a 391-patient trial, but placebo response rates and detailed safety data have not yet been disclosed, and a direct comparison with an existing drug remains ongoing.